Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
The class II myosin MYH4 safeguards genome integrity and suppresses tumor progression
Jayashree Thatte, Ana Moisés da Silva, Judit Börcsök, Thorkell Gudjónsson, Jan Benada, Xin Li, Muthiah Bose, Hanneke van der Gulden, Ji-Ying Song, Renée Menezes, Elena Martín-Doncel, Luis Toledo, Valdemaras Petrosius, Cord Brakebusch, Jos Jonkers, Finn Cilius Nielsen, Maria Rossing, Claus S. Sørensen
Jayashree Thatte, Ana Moisés da Silva, Judit Börcsök, Thorkell Gudjónsson, Jan Benada, Xin Li, Muthiah Bose, Hanneke van der Gulden, Ji-Ying Song, Renée Menezes, Elena Martín-Doncel, Luis Toledo, Valdemaras Petrosius, Cord Brakebusch, Jos Jonkers, Finn Cilius Nielsen, Maria Rossing, Claus S. Sørensen
View: Text | PDF
Research Article Cell biology Clinical Research Oncology

The class II myosin MYH4 safeguards genome integrity and suppresses tumor progression

  • Text
  • PDF
Abstract

Loss-of-function mutations in genome maintenance genes fuel tumorigenesis through increased genomic instability. A subset of these tumor suppressors are challenging to identify due to context dependency, including functional interactions with other genes and pathways. Here, we searched for potential causal genes that impact tumor development and/or progression in breast cancer through functional-genetic screening of candidate genes. MYH4, encoding a class II myosin, emerged as a top hit impacting genomic stability. We show that MYH4 suppresses DNA replication stress by promoting replication licensing and replication fork progression. Moreover, we observed a strong synergistic relationship among class II myosins in suppressing replication-associated DNA damage. Genomic analysis of Pan-Cancer Analysis of Whole Genomes project breast cancer samples revealed frequent concomitant loss of TP53 with MYH4 and class II myosins on chromosome 17p. Notably, Myh4 disruption accelerated mouse mammary tumorigenesis in a Trp53-deficient background. In conclusion, our results suggest an unanticipated function of MYH4 in p53-mediated tumor suppression that can explain their combined loss in breast cancer.

Authors

Jayashree Thatte, Ana Moisés da Silva, Judit Börcsök, Thorkell Gudjónsson, Jan Benada, Xin Li, Muthiah Bose, Hanneke van der Gulden, Ji-Ying Song, Renée Menezes, Elena Martín-Doncel, Luis Toledo, Valdemaras Petrosius, Cord Brakebusch, Jos Jonkers, Finn Cilius Nielsen, Maria Rossing, Claus S. Sørensen

×

Figure 4

Class II myosins exhibit codependency and suppress replication-associated DNA damage.

Options: View larger image (or click on image) Download as PowerPoint
Class II myosins exhibit codependency and suppress replication-associate...
(A) Diagram illustrating chromosome 17 and the genes located in the vicinity of the MYH4 locus. (B) A scheme depicting experimental design and timeline. (C) A representative matrix depicting the dose-response relationship for cell viability in U2OS cells following transfection with specified siRNA pairs for a duration of 72 hours, with various siRNA concentrations. The values represent the mean of 3 replicates, normalized to siUNC and calculated as a percentage of cell death. (D) The Bliss synergy map corresponding to data in panel B is presented. (E) A bar chart showing percentage survival of cells transfected with indicated siRNAs at 6 nM concentration each, for 72 hours (related to C). Data presented as mean ± SD, n = 3. ***P < 0.001 by 1-way ANOVA with Šidák’s multiple-comparison test. NS, not significant. (F) QIBC plot indicating EdU incorporation of U2OS cells transfected with the indicated siRNAs (6 nM each) for 48 hours. Dashed line: Average EdU intensity. (G) QIBC plot of cells transfected with the indicated siRNAs (6 nM each) for 48 hours. Top panel: The distribution of γH2AX. γH2AX color threshold: gray, minimum; red, average; maroon, maximum. Bottom panel: The distribution of chromatin-bound (CB) p-RPA (S33) in different cell cycle phases. CB p-RPA (S33) color threshold: gray, minimum; magenta, average; purple, maximum. (H) Box-and-whisker plot (related to G, top panel) showing mean intensity of γH2AX in S phase of cells transfected with indicated siRNAs (6 nM each) for 48 hours. (I) Box-and-whisker plot (related to G, bottom panel) showing mean intensity of CB p-RPA (S33) in S phase of U2OS cells transfected with indicated siRNAs (6 nM each) for 48 hours. In H and I, middle lines indicate medians, thick boxes indicate lower (25th, Q1) and upper (75th, Q3) quartiles, and whiskers are at 10th and 90th percentiles. The data points are from a single experiment, representative of 3 independent experiments.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts